Journal of Vascular Surgery
Volume 47, Issue 3 , Pages 513-522 , March 2008

Markers of instability in high-risk carotid plaques are reduced by statins

  • Hagen Kunte, MD

      Affiliations

    • Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • Corresponding Author InformationReprint requests: Hagen Kunte, MD, Department of Neurology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
    • ,
  • Nicola Amberger, MD

      Affiliations

    • Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Markus Alexander Busch, MD, MPH

      Affiliations

    • Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Ralph-Ingo Rückert, MD, PhD

      Affiliations

    • Department of Surgery, Franziskus-Krankenhaus, Berlin, Germany.
    • ,
  • Silke Meiners, PhD

      Affiliations

    • Department of Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Lutz Harms, MD

      Affiliations

    • Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Received 20 July 2007 ,Accepted 13 November 2007.

References 

  1. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382–390
  2. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. Stroke. 2000;31:774–781
  3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  4. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  5. Bassiouny HS, Sakaguchi Y, Mikucki SA, McKinsey JF, Piano G, Gewertz BL, et al. Juxtalumenal location of plaque necrosis and neoformation in symptomatic carotid stenosis. J Vasc Surg. 1997;26:585–594
  6. Carr SC, Farb A, Pearce WH, Virmani R, Yao JS. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery. 1997;122:757–763
  7. Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998;29:1625–1630
  8. Lehtonen-Smeds EM, Mayranpaa M, Lindsberg PJ, Soinne L, Saimanen E, Jarvinen AA, et al. Carotid plaque mast cells associate with atherogenic serum lipids, high grade carotid stenosis and symptomatic carotid artery disease (Results from the Helsinki carotid endarterectomy study). Cerebrovasc Dis. 2005;19:291–301
  9. Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 2005;20:141–151
  10. Higashikata T, Yamagishi M, Higashi T, Nagata I, Iihara K, Miyamoto S, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: Results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis. 2006;185:165–172
  11. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study (The Care Investigators). Circulation. 1999;99:216–223
  12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group). N Engl J Med. 1998;339:1349–1357
  13. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002;106:1690–1695
  14. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–767
  15. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  16. Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005;25:1093–1110
  17. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev. 2003;2:332–338
  18. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712–1719
  19. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276–283
  20. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671–1678
  21. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–933
  22. Verhoeven BA, Moll FL, Koekkoek JA, van der Wal AC, de Kleijn DP, de Vries JP, et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke. 2006;37:2054–2060
  23. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis (North American Symptomatic Carotid Endarterectomy Trial Collaborators). N Engl J Med. 1991;325:445–453
  24. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation. 2006;113:2320–2328
  25. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques (A potential role in acute plaque disruption). Stroke. 2000;31:40–47
  26. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103:276–283
  27. Serrano CV, Yoshida VM, Venturinelli ML, D’Amico E, Monteiro HP, Ramires JA, et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis. 2001;157:505–512
  28. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057–2064
  29. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem. 2005;280:6627–6633
  30. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke. 2001;32:850–854
  31. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. Stroke. 2000;31:774–781
  32. Li C, Mollahan P, Baguneid MS, McMahon RF, Kumar P, Walker MG, et al. A comparative study of neovascularisation in atherosclerotic plaques using CD31, CD105 and TGF beta 1. Pathobiology. 2006;73:192–197
  33. Kawahara I, Kitagawa N, Tsutsumi K, Nagata I, Hayashi T, Koji T. The expression of vascular dendritic cells in human atherosclerotic carotid plaques. Hum Pathol. 2007;38:1378–1385
  34. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363:915–924
  35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  36. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902–2909
  37. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis. 2007;24:170–182

 Competition of interest: none.

 CME article

PII: S0741-5214(07)01892-7

doi: 10.1016/j.jvs.2007.11.045

Journal of Vascular Surgery
Volume 47, Issue 3 , Pages 513-522 , March 2008

Article Tools

* Image Usage & Resolution